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Background: Model replication is important because it enables researchers to check research integrity and transparency and,
potentially, to inform the model conceptualization process when developing a new or updated model.
Objective: The aim of this study was to evaluate the replicability of published decision analytic models and to identify the
barriers and facilitators to replication.
Methods: Replication attempts of 5 published economic modeling studies were made. The replications were conducted using
only publicly available information within the manuscripts and supplementary materials. The replicator attempted to
reproduce the key results detailed in the paper, for example, the total cost, total outcomes, and if applicable, incremental cost-
effectiveness ratio reported. Although a replication attempt was not explicitly defined as a success or failure, the replicated
results were compared for percentage difference to the original results.
Results: In conducting the replication attempts, common barriers and facilitators emerged. For most case studies, the rep-
licator needed to make additional assumptions when recreating the model. This was often exacerbated by conflicting in-
formation being presented in the text and the tables. Across the case studies, the variation between original and replicated
results ranged from 24.54% to 108.00% for costs and 23.81% to 0.40% for outcomes.
Conclusion: This study demonstrates that although models may appear to be comprehensively reported, it is often not enough
to facilitate a precise replication. Further work is needed to understand how to improve model transparency and in turn
increase the chances of replication, thus ensuring future usability.
Keywords: decision-analytic modeling, replication, reporting transparency, reproducibility.
VALUE HEALTH. 2019; -(-):-–-Introduction reported,3–5 and a proxy for such transparency could be to assessComputer programs have been labeled as black boxes1 owing
to their underlying code frequently being withheld. In a similar
vein, health economic decision models may be perceived as black
boxes given that often, the underlying equations, assumptions,
and input parameters are sparsely reported. As well, industry
submissions to health technology assessments may include pro-
prietary data inputs with limited accessibility.2 This limits the
ability of others to interrogate and replicate models, potentially
damaging research integrity, because reporting and methodolog-
ical quality cannot easily be assessed. With this in mind, main-
taining a high level of transparency in the development and
reporting of decision models is essential. Increasingly, there are
calls for greater transparency in the way modeling studies areof interest: The authors have indicated that they have no conflicts of inter
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15 - see front matter Copyright ª 2019, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/lic
doi.org/10.1016/j.jval.2019.04.1928whether or not the model is replicable.
There is growing consensus that an independent modeler
should be able to reproduce the results of a model on the basis of
only the published information.5,6 Publications by the Interna-
tional Society for Pharmacoeconomics and Outcomes Research &
The Society for Medical Decision Making Task Force provide an
explicit definition of a transparent model. Significantly, this defi-
nition cites the process of replication, suggesting that the ability
to replicate a model may indicate that it is transparent: “Trans-
parency serves 2 purposes: 1) to provide a non-quantitative
description of the model . and 2) to provide technical infor-
mation to readers who want to evaluate a model at higher levels
of mathematical and programming detail, and possibly replicate
it.”5est with regard to the content of this article.
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2 VALUE IN HEALTH - 2019In another publication by the Task Force, the importance of
transparency is repeated, stating that “a model should not be a
‘black box’ for the end-user but be as transparent as possible, so
that the logic behind its results can be grasped at an intuitive
level.”6 Sampson et al suggest that although calls for model
transparency have been numerous, “there are few signs of
improvement in practice.”7 This is echoed in a study focusing on
models used within oncology, concluding that “there is a need for
elevated rigor and transparency of reporting,”3 although exactly
how this might be achieved is not discussed.
Aside from increased transparency, replicable models have
practical benefits in potentially reducing research waste and
researcher time if they can be used when developing future
models, as advocated by the REWARD alliance.8 For example, if
existing models were easily replicable, future modelers might be
able to use such models as a springboard in developing others,
leaving more time to devote to validation work. Furthermore,
Chilcott et al9 discuss the concept of replication as a method to
check the face validity (ensuring results and structure make
intuitive sense10) of models in the development process, and cite
the potential benefits of replicating a model using different
software.
Currently, the existing literature looking at replicating the re-
sults of published modeling studies is small.11–13 Most recently,
the collaborative diabetes modeling group, Mt Hood, published
the results of their 2016 conference meeting focusing on
“Research Transparency,” which set modelers the challenge of
replicating 2 diabetes simulation models.13,14 Owing to the diffi-
culties incurred during these replications, Mt Hood published a
checklist designed to facilitate the reporting of model inputs
specific to diabetes. More generally, decision models are subject to
quality and reporting checklists, such as Consolidated Health
Economic Evaluation Reporting Standards15 or Philips.10
This study looked to replicate several decision models across a
variety of disease areas, examining the reasons facilitating or
preventing replication and also exploring whether current
reporting standards adequately facilitate replication. In doing so, it
is hoped that this paper will highlight ways in which future
modeling studies can be reported, for greater understanding by
readers and to facilitate replication.Methods
Five modeling studies were selected for replication, with each
of the replication attempts detailed as case studies. The rationale
for selecting these original publications varied. For case studies 1,
2, and 3, each of the models were identified through a systematic
review of models within that disease area.16 The models selected
for replication were considered to be the most thoroughly re-
ported (in the most number of Philips Checklist criteria satisfied10)
and therefore were considered most likely to be replicable. The
final model replications, case studies 4 and 5, were pragmatic,
arising from the need to develop a model for a similar decision
problem. The original model detailed in case study 4 was chosen
because it had characteristics and health states that made it
suitable for adaptation to address a specific question, whereas the
model replicated within case study 5 was selected because it was
the most up to date and contextually relevant.
The primary focus of the replication attempts was to recreate
the key figures presented in the text, such as total cost, outcomes,
and if applicable, incremental cost-effectiveness ratio (ICER), for
the base case analyses. The replication did not extend to sensi-
tivity analysis; nevertheless, for one of the pragmatic case studies,
probabilistic sensitivity analysis was replicated, and the results ofthis are discussed. The degree to which the original results varied
in comparison to the replicated results were calculated as a per-
centage difference.12
As with the manuscripts in case studies 1 through 3, the Philips
Checklist was also completed for case studies 4 and 5, with the
intention of exploring whether any barriers and facilitators iden-
tified in the replications related to items within the checklist. For
each of the criteria, a subjective response of yes, no, partial, or not
applicable was given. If it were found that the barriers were not
picked up within the checklist or indeed that they were deemed to
be suitably reported, it might suggest that existing reporting
criteria are insufficient.
The replication studies were conducted by separate authors
and were done so using only the information presented in the
referenced publications. Where possible, the same software as in
the original publication was used in the replication. Importantly,
publications were not selected to intentionally single out indi-
vidual authors, journals, institutions, clinical areas, or modeling
methodologies. Also, the inability to replicate a model does not
necessarily infer errors within the model, but merely a lack of
information within the report or even the inability of the person
replicating the study. In the same respect, the ability to replicate
may not necessarily indicate model quality given that a model
may be transparently reported, but with inappropriate assump-
tions given the clinical condition or population being modeled.Results
The general characteristics of the models, the scenarios
selected for replication, and the characteristics of the replicator
are detailed in Table 1. Responses to the Philips Checklist criteria
are provided in Table 2. It was found that most criteria were ful-
filled. The items that were considered partially or not completed
among the studies were mostly concerning the quality of the
model, as opposed to the reporting detail that would facilitate
replication. The results of the replications compared to the orig-
inal publication, along with any differences, are shown in Table 3.
The replications highlighted the following general facilitators
to replication:
 detailed diagram of the model structure
 example calculations provided (for both costs and outcomes)
 clear tables of assumptions
Conversely, the following factors were found to be barriers to
replication:
 conflicting or inadequate information to inform model param-
eters or model structure
 uncertainty about assumptions made about parameters or
model structure
 for models with longer time frames, any difference in as-
sumptions due to lack of information was compounded,
resulting in greater variation between original and replicated
results
 inability to clarify a model with the original author
These are illustrated within the context of the 5 case studies
below.
Case Study 1
The first replication was of a state-transition model developed
using Microsoft Excel, described in a Health Technology Assess-
ment monograph.17 The model evaluated calcineurin inhibitors for
Table 1. Description of the models included within each of the case studies
Case
study
Replicator
category
of
experience*
First
author
(Year)
Model
type
Disease Population Intervention /
comparator
Perspective Software Time
horizon
(cycle
length)
Health
outcome
1 2 Garside
(2005)
State-
transition,
cohort
Atopic
eczema
Adults with
mild to
moderate
facial
eczema
Pimecrolimus/TCS NHS Microsoft
Excel
1 year
(4 weeks)
QALY
State-
transition,
cohort
Atopic
eczema
Children with
moderate to
severe body
eczema
Tacrolimus/TCS NHS Microsoft
Excel
14 years
(4 weeks)
QALY
2 1 Dean
(2001)
Decision
tree
Erosive
reflux
esophagitis
“Ambulatory
care patients”
Rabeprazole,
omeprazole,
lansoprazole
Third-party
payer
Data
TreeAge
1 year
(not
applicable)
Percentage
of
symptomatic
recurrences
prevented
3 1 Affleck
(2011)
State-
transition,
cohort
Psoriasis Adults with
moderately
severe scalp
psoriasis
TCF gel/first-line
therapy BMV
NHS in
Scotland
Microsoft
Excel
1 year
(4 weeks)
QALY
4 3 Chambers
(1999)
State
transition,
cohort
Stroke Stroke
survivors
Antiplatelet
therapy for
prevention of
recurrent stroke
Broad
health
and
social
care
Data
TreeAge
Base case:
5 years,
extended
to 25 years
(3 months)
Number
of
strokes,
life-years
5 3 Ganesa
lingam
(2015)
Decision
tree
State-
transition,
cohort
Stroke
(acute)
Adults who
had
an acute stroke
Mechanical
thrombectomy/
IV-tPA
NHS Software
not stated
20 years
(3 months)
QALY
BMV indicates betamethasone valerate; IV-tPA, intravenous tissue-type plasminogen activator; NHS, National Health Service; QALY, quality-adjusted life-year; TCF, two-
compound formulation; TCS, topical corticosteroid.
*Replicator experience defined according to the following categories:
1. recent training in decision modeling as part of an MSc in health economics (The replication was conducted as part of an MSc dissertation with supervision from 2
health economists of category 2/3 experience.)
2. early career researcher with a background in mathematics and an MSc in health economics (over 4 years’ experience)
3. experienced health economist with significant experience of decision modeling (8 to 20 years’ experience)
All replicators were new to the clinical area of the model they replicated.
-- 3the treatment of eczema in both adults and children, across 8
scenarios. These scenarios were divided into population (adults or
children), location of eczema (facial or body), and severity (mild to
moderate or moderate to severe). For this case study, 2 scenarios
were chosen for replication, which encompassed the widest range
of options: the first evaluated pimecrolimus for the treatment of
mild to moderate facial eczema within adults, and the second
evaluated tacrolimus for moderate to severe body eczema among
children. The models were constructed using treatment states
composed of different disease severity mixes, allowing for the fact
that different disease severities could receive the same treatment
yet have different utilities.
The results of the adult scenario replication varied by 22.84%
to 16.49% for costs and 0.00% to 0.31% for outcomes, and the same
overall conclusion regarding cost-effectiveness was found (topical
corticosteroids dominated). While replicating the childhood sce-
nario, however, it became evident that numerous additional as-
sumptions were required. Owing to this and the extended time
horizon of 14 years, any differences between the original and
replicated model per cycle were amplified, resulting in the repli-
cated model returning values that were far removed from the
original results (costs varying by 108% of those reported origi-
nally). Therefore, no attempts to replicate other treatmentpathways within this scenario were made. Although the costs
were far removed, the outcomes replicated were relatively close to
the original values (varying by 22.29%), which may suggest that
rather than outright replicator error, the variation may have
resulted from misinterpretation of costing assumptions.
The main barrier within this replication was the way in which
the multiple scenarios, based on modifications of a general model,
were presented. Although the transition probabilities were given,
they were for all of the 8 different scenarios together, with no
clear labeling as to which transition probabilities related to which
scenario. In addition, some of the transition probabilities were
instead presented as the likelihood of patients being offered
different treatments owing to a previously failed a treatment. This
was further complicated by conflicting information within the text
and the transitions presented in the table. For example, when
recreating the adult scenario, it was stated that after a failed
treatment of low-potency steroids, the probability that a patient
would receive pimecrolimus was 0.85, mid-potency steroids 0.1,
and high-potency steroids 0.05. Nevertheless, this conflicted with
information in the text, stating high-potency steroids were not a
treatment option within this scenario. Consequently, this left a
0.05 probability to be allocated to a treatment with no description
about how this should be done. An author of the original
Table 2. Responses to the Philips checklist criteria10 for all of the
modeling studies replicated
Checklist item Case study
1 2 3 4 5
Is there a clear
statement of the decision problem?
y y y y y
Is the objective of the
evaluation and model specified and
consistent with the stated decision
problem?
y y y y y
Is the primary decision maker
specified?
y y y y y
Is the perspective of the model
stated clearly?
y y y y y
Are the model inputs consistent
with the stated perspective?
y y y y y
Has the scope of the model
been stated and justified?*
y y y y y
Are the outcomes of the model
consistent with the perspective,
scope, and overall objective
of the model?
y y y y y
Has the evidence regarding
the model structure been described?*
y n y y n
Is the structure of the model
consistent with a coherent
theory of the health condition
under evaluation?
y y y y y
Have any competing theories
regarding model structure been
considered?
y n n n n
Are the sources of data
used to develop the structure
of the model specified?*
y n y n n
Are the causal relationships
described by the model structure
justified appropriately?
y y y y y
Are the structural
assumptions transparent
and justified?*
y y y y y
Are the structural assumptions
reasonable given the overall objective,
perspective, and scope of the model?
y y y y y
Is there a clear definition
of the options under evaluation?*
y y y y y
Have all feasible and
practical options been evaluated?
y y y y y
Is there justification for
the exclusion of feasible options?
y n/a n/a n/a n/a
Is the chosen model type a
ppropriate given the decision
problem and specified
causal relationships within the model?
y n y y y
Is the time horizon of the model
sufficient to reflect all important
differences between options?
y n y y y
Is the time horizon of the model,
and the duration of treatment and
treatment effect, described and
justified?*
y y y y y
Continued on next column
Table 2. Continued
Checklist item Case study
1 2 3 4 5
Has a lifetime horizon been used?
If not, has a shorter time
horizon been justified?
n n n y y
Do the disease states
(state transition model)
or the pathways (decision
tree model) reflect
the underlying biological
process of the disease in question
and the impact of interventions?
y y y y y
Is the cycle length defined and
justified in terms of the natural
history of disease?*
p n/a y p p
Are the data identification
methods transparent and
appropriate given the objectives
of the model?
y y y y y
Where choices have been
made between data sources,
are these justified appropriately?
y n/a y n/a n/a
Has particular attention been
paid to identifying data for the
important parameters in the model?
y y y y y
Has the process of selecting key
parameters been justified and
systematic methods used to identify
the most appropriate data?
y y y y y
Has the quality of the data been
assessed appropriately?
y y y y n
Where expert opinion has been
used, are the methods described and
justified?
p p y y n/a
Are the pre-model data analysis
methodology based on justifiable
statistical and epidemiological
techniques?
y y y y y
Is the choice of baseline data described
and justified?*
y y y y y
Are transition probabilities
calculated appropriately?*
y y y y y
Has a half cycle correction
been applied to both cost
and outcome?*
n n/a n n n
If relative treatment effects
have been derived from trial
data, have they been synthesized
using appropriate techniques?
y y y y y
Have the methods and assumptions
used to extrapolate short-term
results to final outcomes been
documented and justified? Have
alternative assumptions been
explored through sensitivity analysis?*
y y y y y
Have assumptions regarding the
continuing effect of treatment once
treatment is complete been
documented and justified? Have
alternative assumptions been
explored through sensitivity analysis?*
y y n y y
continued on next page
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Table 2. Continued
Checklist item Case study
1 2 3 4 5
Are the utilities
incorporated into the
model appropriate?
y n/a y n/a y
Is the source for the
utility weights referenced?*
y n/a y n/a y
Are the methods of
derivation for the utility
weights justified?
y n/a y n/a y
Have all data incorporated
into the model been described and
referenced in sufficient detail?*
y y y y y
Has the use of mutually
inconsistent data been justified
(ie, are assumptions and choices
appropriate)?
n/a n/a n/a n/a n/a
Is the process of data
incorporation transparent?*
y y y y y
If data have been incorporated as
distributions, has the choice of
distribution for each parameter been
described and justified?*
n/a n/a n/a n/a p
Have the 4 principal types of
uncertainty been addressed?
p p p p p
If not, has the omission of particular
forms of uncertainty been justified?
n n n n n
Have methodological uncertainties
been addressed by running alternative
versions of the model with different
methodological assumptions?
n n n y n
Is there evidence that structural
uncertainties have been addressed via
sensitivity analysis?
n y n n y
Has heterogeneity been dealt with by
running the model separately for
different subgroups?
y n n n n
Are the methods of assessment of
parameter uncertainty appropriate?
y y y y y
Has probabilistic sensitivity analysis
been done? If not, has this been justified?
y n n n y
If data are incorporated as point
estimates, are the ranges used for
sensitivity analysis stated and justified?*
y y p y p
Is there evidence that the mathematical
logic of the model has been tested
thoroughly before use?
n n n n n
Are the conclusions valid given the
data presented?
y y y y y
Are any counterintuitive results
from the model explained and justified?
n/a n/a n/a n/a n/a
If the model has been calibrated
against independent data, have any
differences been explained and justified?
y n/a n/a n/a n/a
Have the results of the model
been compared with those of
previous models and any differences
in results explained?
y n y y y
Note. Where it was unclear if a criterion was satisfied, the reviewer erred on the
side of caution and responded no.
N indicates no; N/A, not applicable; P, partial; Y, yes.
*These were identified as criteria that might have the greatest influence on the
replicability of a modeling study given that they directly related to reporting of
items needed for replication.
-- 5publication was contacted to provide clarification but was unable
to help, citing the time that had passed since the publication and
current workload.
Facilitators:
 detailed diagrams of the model structures, clearly depicting
possible transitions
Barriers:
 areas where the text and tables conflicted
 grouping of transition probabilities, instead of presenting the
values for each of the scenarios individually
 extended modeling time horizon meant any differences be-
tween the replicated and original model were amplified over
time (in the childhood scenario)
 unable to obtain clarification from the authorsCase Study 2
This case study replicated a decision tree, modeling the use
of proton pump inhibitors for the maintenance therapy of
erosive reflux esophagitis over a 1-year time horizon,18 using
Microsoft Excel (instead of TreeAge, as used in the original
study). The manuscript included a figure clearly showing the
tree structure and a table of the probabilities used. These
enabled the replicated model to closely compare to the original,
outcomes were matched exactly, and costs ranged only
by 24.43% to 1.20%.
Despite the simplicity of the decision tree, there were still
some barriers to successful replication. These included discrep-
ancies between the text and branch structure presented in the
model diagram (which was later assumed to be purely descriptive)
along with a lack of clarity surrounding how to cost the treat-
ments used as maintenance therapy.
Facilitators:
 simplistic model structure
Barriers:
 conflicting information between the text and model diagram
 lack of clarity regarding how costs were attributed during
maintenance therapyCase Study 3
Affleck et al19 described a 15-state state-transition model, built
to evaluate treatment approaches for scalp psoriasis using 4
weekly cycles over a 1-year time horizon. Treatment pathways 1
and 5 were replicated.
The model was described comprehensively with tables of
the transition probabilities, utilities, and descriptions of the
health states being provided. In addition, a detailed diagram of
both the model and the different treatment pathways being
evaluated was given. This enabled the replicated outcomes to
vary from the original publication by only 0.37% and 0.40%
across the 2 pathways, whereas the costs varied by 24.54% and
0.07%.
Only minor barriers to replication were found, involving the
way some of the costs, assigned to each of the health states, were
described. Particularly, it was stated that a “weighted average of
treatment modalities” was costed, although the weightings were
not given.
Table 3. Per-patient results of the replication attempts in comparison to the original results reported in the publication
Scenario
Replicated
Results
Cost per patient Health outcome per patient
Original Replication Difference (%) Original Replication Difference (%)
Case
Study 1
Base case (adults, no pimecrolimus) 39.39 38.27 21.12 (22.84%) 0.968 0.968 0.000 (0.00%)
Adults, pimecrolimus as
second-line treatment
70.58 79.69 9.11 (12.91%) 0.961 0.964 0.003 (0.31%)
Adults, pimecrolimus
as first-line treatment
135.44 157.78 22.34 (16.49%) 0.967 0.967 0.000 (0.00%)
Base case (children, no
tacrolimus)
956.47 1989.44 1032.97 (108.00%) 1.085 1.060 20.248 (22.29%)
Case
Study 2
Rabeprazole 1414 1431 17 (1.20%) 86 86 0 (0.00%)
Lansoprazole 1671 1597 274 (24.43%) 68 68 0 (0.00%)
Omeprazole 1599 1581 218 (21.13%) 81 81 0 (0.00%)
Case
Study 3
Base case (TCF gel as first-line
therapy)
241.86 230.89 210.97 (24.54%) 0.7818 0.7847 0.003 (0.37%)
First-line therapy as BMV 255.12 255.29 0.17 (0.07%) 0.7801 0.7832 0.003 (0.40%)
Case
Study 4
No treatment (5-year time horizon) 15 093 14 955 2138 (20.91%) 3.911 3.981 0.070 (1.79%)
Aspirin (5-year time horizon) 14 817 14 717 2100 (20.67%) 3.918 3.989 0.071 (1.81%)
No treatment (25-year time horizon) 24 881 25 858 977 (3.93%) 7.607 7.585 20.022 (20.29%)
Aspirin (25-year time horizon) 24 491 25 503 1012 (4.13%) 7.664 7.643 20.021 (20.27%)
Case
Study 5
Base case (IV-tPA) 52 495 53 545 1050 (2.00%) 3.790 3.795 0.005 (0.13%)
Thrombectomy 64 757 65 656 899 (1.39%) 4.842 4.800 20.042 (20.87%)
Note. % difference calculated using the following formula: ((Replication – Original) / Original) 3 100%.
BMV indicates betamethasone valerate; IV-tPA, intravenous tissue-type plasminogen activator; TCF, two-compound formulation; TCS, topical corticosteroid.
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 A comprehensive table was provided that detailed the different
health states of the model at baseline, any assumptions, and the
possible transitions from the state.
Barriers:
 Ambiguity surrounding the weighted average used when
calculating the cost of treatments.Case Study 4
In this case study, a state-transition model developed by
Chambers et al20 evaluating the use of aspirin for stroke survivors
was replicated. In addition, some values were taken from a later
paper by the same authors.21 This model was run in the base case
over 5 years and in other iterations, over a 2- and 25-year time
horizon. Attempts were made to replicate the results from both
the 5- and 25-year analyses using Microsoft Excel.
In the base case, costs were replicated to within 20.91%
and 20.67%, and outcomes were within 1.79% and 1.81% in com-
parison to the original. Increased variation in costs was seen when
the time horizonwas extended to 25 years, with variation of 3.93%
and 4.13%.
There was uncertainty relating to some parameters. This was
due to the table giving a range for each of the parameters, instead
of listing individual values for each of the time points. This
simplified reporting but made it unclear what value was used in
particular cycles. In addition, some values were reported with
limited numbers of decimal places. In the model replication, total
long-term costs over 25 years were overestimated by approxi-
mately 4%. Although total estimates of life-years were very similar,
there were small discrepancies as disabled life-years were slightly
overestimated and disability-free life-years were slightlyunderestimated. Long-term care costs were the largest cost, and
estimates per cycle were much higher for disabled stroke survi-
vors, so this would account for the additional estimate of cost.
Therefore, very small discrepancies in the number of individuals in
disabled states had the potential for larger discrepancies in ex-
pected costs.
Facilitators:
 Tables detailing how the main cost parameters were derived,
along with a complete table of costs entered in the model,
greatly facilitated the model replication.
Barriers:
 Rangesweregiven for theparameters insteadof individual values.
Case Study 5
The final case study focused on an evaluation conducted by
Ganesalingam et al22 comparing mechanical thrombectomy to
standard care alone, intravenous tissue-type plasminogen acti-
vator (IV-Tpa), in cases of acute stroke. Analyses were carried out
using a combined short-term decision tree and state-transition
cohort model. The time horizon was 20 years with discounting
of costs and outcomes at 3.5%. A hypothetical cohort of 1000 pa-
tients was used in a simulation (replicated using Microsoft Excel,
original software not stated).
The replication resulted in costs that varied by 2.00% and 1.39%
in comparison to the original, whereas the outcomes varied by
0.13% and 20.87%. This case study was the only one where the
interventions were not dominant or dominated, and so the ICER
was also replicated. The original ICER was £11 651 per QALY in
comparison to £12 051 when using the replicated values, a total of
3.43% variation.
The model was thoroughly reported in the publication, with a
diagram provided and all of the parameters required to recreate
-- 7the main analyses clearly listed in a table. The cost per cycle for 2
of the model states was also given, which further facilitated the
replication.
Despite the parameters being comprehensively reported,
several barriers to replication were still encountered, which
required additional assumptions. These included uncertainty
about the allocation of treatment costs after recurrent stroke and
how discounting was applied. It was unclear whether the first
cycle was considered as time 0 (given that 3 months was meant to
have elapsed within the decision tree) and whether the cycles
within the first year were or were not discounted.
Moreover, when trying to recreate some of the probabilistic
sensitivity analyses conducted, it was apparent that not all of the
distribution parameters were included in the publication, and
although some of these were available in online supplementary
materials, additional assumptions about the distributions used
were required. Furthermore, the shape parameters reported for
the beta distributions to generate utilities were implausible
because they generated values that were far lower than the point
estimates.
While carrying out this replication, an attempt was made to
contact 2 of the authors to ask if they would be willing to share the
original model code, but no response was received.
Facilitators:
 Model parameters were clearly listed.
 Examples of costs per cycle were given for 2 of the model states.
Barriers:
 Ambiguity about the assumptions made with treatment costs
after recurrent stroke.
 Lack of clarity surrounding the 3-month decision tree and how
this affected subsequent cycle discounting.
 Not all of the distributions used in the probabilistic sensitivity
analyses were listed and implausible shape parameters given
for the beta distributions.
 Unable to obtain clarification from the authors.Discussion
The aforementioned case studies have highlighted several
common barriers and facilitators to model replication. Facilitators
to model replication included the provision of clear model dia-
grams that detailed all potential transitions and clearly reporting
transition probabilities alongside the treatment pathways. More-
over, documenting the cost per cycle for model states (as was seen
in case study 5), and providing example calculations for transi-
tions, greatly facilitated model replication.
Common barriers to replication included conflicting informa-
tion being presented in the text in comparison to what was pre-
sented in model diagrams or tables. Moreover, although all of the
papers provided some sort of table describing the model input
parameters, often these were grouped for multiple treatment
pathways or time horizons, instead of being specific. In doing this,
it was difficult to appreciate which parameter referred to which
model iteration or scenario, and thus was a common barrier to
replicating the analysis. The case studies replicating models with
longer time horizons also proved harder to replicate given that
any, even minor, discrepancies in costs, outcomes, or transition
probabilities between the original and replicated model became
amplified over time. Furthermore, given that in 2 of the case
studies an author was unsuccessfully contacted for clarification,this study should also act as a reminder to modelers to archive and
thoroughly annotate their work to facilitate any future inquiries.
Another finding of the aforementioned replications was the
tendency for greater variation in the replicated costs thanoutcomes,
for example, costs ranged from 24.54% to 108.00%, whereas out-
comes varied by23.81% to 0.40%. Thismight suggest that additional
emphasis is needed when reporting the unit costs and assumptions
about resource use to assist with greater accuracy in model
replication.
Moreover, in all of the case studies, it initially appeared that
the original publications comprehensively reported the technical
aspects of the decision models chosen for replication, as shown by
the fact that most of the Philips Checklist criteria received a
favorable response. Given that several common barriers were still
encountered, however, suggests that the Philips Checklist may not
be an entirely reliable means by which to ensure studies are
replicable. This might be because the Philips Checklist focuses
more on model quality, in that appropriate justifications are given
as opposed to reporting clarity. These findings are similar to those
reported by the Mt Hood conference focusing on transparency,14
which referred to the commonly used Philips10 and Consolidated
Health Economic Evaluation Reporting Standards15 checklists as
being potentially “overly general to satisfy the needs in compli-
cated multifactorial disease areas” to facilitate their replication. It
remains to be seen if the checklist they went on to develop fa-
cilitates future replication attempts or if indeed other strategies
need to be considered.13
If future model replications are to be facilitated, then a
formalized process of how models are presented, instead of
further checklists, is required. For example, while providing a table
of input parameters may appear to be enough to satisfy a checklist
item, it may not be apparent until a replication is conducted, if any
parameters have been omitted.
Suggestions of ways to present models to facilitate replication
might include a table with the total costs associated with each
state. In providing these values, any implicit assumptions that the
modeler had failed to document in the manuscript could be
deciphered. Although these recommendations may be feasible
when describing state-transition models, transparent reporting is
likely to be far more challenging with complex models such as
discrete event simulations. Given that models with a longer time
horizon were found harder to replicate, it might be of use to
provide a summary of results for a short-term value (for example,
a year) so that a replicator could check against these before
running the model over many more cycles (and thus inflating any
inherent discrepancies).
A more thorough presentation of model structure and other
elements could also be encouraged by changing workflow prac-
tices to give more consideration to replicability. Replication of the
model programming by 2 separate individuals within the study
team, both working from the same analysis plan, would encourage
clear and unambiguous descriptions of model structure. This type
of redundancy in workflow is already commonly practiced by
statisticians analyzing clinical trial data and in software develop-
ment (chapter 9.7.9, Quality Control23).
Although this study has focused on how authors could present
their modeling studies to facilitate easier replication, other factors
such as journal data sharing policies, word limits, and the use of
supplementary materials should also be acknowledged as
contributing factors. In addition, if model registries7,24 or the
publishing of open source models25 were more commonplace,
replication may be more easily facilitated, given that a replicator
could access and inspect model code (albeit that this would still
require detailed annotation to be understood by a third party).
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Although the spectrum of clinical conditions from which the
modeling studies were selected was intended to be broad, in most
case studies, a deterministic state-transition model was replicated,
and therefore the findings might not be generalizable to other,
more complex model types. There was also a limited range of
modeling software used, and therefore the potential benefits or
difficulties of using other software, such as R, were not explored.
The results of the replications are highly dependent on the com-
petencies of the replicator and therefore may not necessarily be a
true reflection on the quality or replicability of the model within
the original publication. Attempts were made to mitigate this,
however, by using different modelers for each of the case studies,
each of whom had varying levels of experience. Importantly, none
of the case studies were chosen to single out any author, institu-
tion, or journal.
Conclusion
It is hoped that this study will act as a catalyst to review the
ways in which models are currently presented. From the case
studies above, it is evident that even if a model appears to be
largely well reported, it may still be difficult to precisely replicate
the results presented, if even a single assumption or parameter
value is omitted. Therefore, a review of how modeling studies are
conducted and presented is required.
Acknowledgments
The authors thank the reviewers of the manuscript for their valuable
comments. They also thank the HESG conference delegates (Gran Canaria,
2016) for their discussion of one of the replications in this paper. Thanks
also go to the authors whose models were replicated in this publication.
The study was funded by the National Institute for Health Research
(NIHR) Collaboration for Leadership in Applied Health Research and Care
(CLAHRC) East of England (project HE7: Dec 2015). Funding for E.M. and T.S.
was also received via T.S.’s Career Development Fellowship (CDF award-
2014-07-006) supported by the NIHR. The views expressed in this paper
are those of the authors and not necessarily those of the National Health
Service, the NIHR, or the Department of Health and Social Care.
REFERENCES
1. Morin A, Urban J, Adams P, et al. Shining light into black boxes. Science.
2012;336(6078):159–160.
2. Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved
conduct of health technology assessments for resource allocation decisions.
Int J Technol Assess Health Care. 2008;24(3):244–258.
3. Beca J, Husereau D, Chan KK, Hawkins N, Hoch JS. Oncology modeling for fun
and profit! Key steps for busy analysts in health technology assessment.
Pharmacoeconomics. 2018;36(1):7–15.4. Padula WV, McQueen RB, Pronovost PJ. Can economic model transparency
improve provider interpretation of cost-effectiveness analysis? Evaluating
tradeoffs presented by the Second Panel on Cost-effectiveness in Health and
Medicine. Med Care. 2017;55(11):909–911.
5. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model
transparency and validation: a report of the ISPOR-SMDM Modeling Good
Research Practices Task Force-7. Value Health. 2012;15(6):843–850.
6. Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for
decision analytic modeling in health-care evaluation: report of the ISPOR
Task Force on Good Research Practices—Modeling Studies. Value Health.
2003;6(1):9–17.
7. Sampson CJ, Wrightson T. Model registration: a call to action. Pharmacoecon
Open. 2017;1(2):73–77.
8. The Reward Alliance. The REWARD statement. http://rewardalliance.net/
reward-statement/. Accessed April 19, 2016.
9. Chilcott J, Tappenden P, Rawdin A, et al. Avoiding and identifying errors in
health technology assessment models: qualitative study and methodological.
Health Technol Assess. 2010;14(25):iii-iv, ix-xii, 1-107.
10. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice
in decision-analytic modelling in health technology assessment. Health
Technol Assess. 2004;8.
11. Bermejo I, Tappenden P, Youn J-H. Replicating health economic models: firm
foundations or a house of cards? Pharmacoeconomics. 2017;35(11):1113–
1121.
12. Smolen LJ, Klein TM, Kelton K. Replication of a published Markov chronic
migraine cost-effectiveness analysis model for purposes of early phase
adaptation and expansion. Value Health. 2015;18(3):A19.
13. Palmer AJ, Si L, Tew M, et al. Computer modeling of diabetes and its trans-
parency: a report on the Eighth Mount Hood Challenge. Value Health.
2018;21(6):724–731.
14. Mt Hood Diabetes Challenge. The Mount Hood 2016 Challenge, Switzerland.
https://docs.wixstatic.com/ugd/4e5824_36cb1fd0aca94f1980d8a2228cf7e6
e8.pdf. Accessed November 14, 2017.
15. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic
evaluation reporting standards (CHEERS) statement. Cost Eff Resource Alloc.
2013;11(1):6.
16. McManus E, Sach T, Levell N. The use of decision–analytic models in atopic
eczema: a systematic review and critical appraisal. Pharmacoeconomics.
2018;36(1):51–66.
17. Garside R, Stein K, Castelnuovo E, et al. The effectiveness and
cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a
systematic review and economic evaluation. Health Technol Assess.
2005;9(29):1–230.
18. Dean BB, Siddique RM, Yamashita BD, Bhattacharjya AS, Ofman JJ. Cost-
effectiveness of proton-pump inhibitors for maintenance therapy of erosive
reflux esophagitis. Am J Health Syst Pharm. 2001;58(14):1338–1346.
19. Affleck AG, Bottomley JM, Auland M, Jackson P, Ryttov J. Cost effectiveness of
the two-compound formulation calcipotriol and betamethasone dipropio-
nate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin.
2011;27(1):269–284.
20. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet
therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics.
1999;16(5):577–593.
21. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of
stroke care in the United States and Europe. Value Health. 2002;5(2):82–97.
22. Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-
utility analysis of mechanical thrombectomy using stent retrievers in acute
ischemic stroke. Stroke. 2015;46(9):2591–2598.
23. Medicines and Healthcare Products Regulatory Agency. Good Clinical Practice
Guide. 9th ed. London, England: The Stationery Office; 2018.
24. Arnold RJ, Ekins S. Ahead of our time: collaboration in modeling then and
now. Pharmacoeconomics. 2017;35(9):975–976.
25. Dunlop WC, Mason N, Kenworthy J, Akehurst RL. Benefits, challenges and
potential strategies of open source health economic models. Pharmacoeco-
nomics. 2017;35(1):125–128.
